EIF5

Across TCGA pan-cancer cohorts, EIF5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EIF5 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher EIF5 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated EIF5 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

BLCA, PRAD, and LGG are the cancer types where EIF5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	1.000	0.333	.037	10	view →
PRAD	DFS	Median	All	0.109	0.776	<.001	6	view →
LGG	OS	Median	All	0.294	0.799	.005	3	view →
UCEC	DFS	Median	All	0.933	0.627	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EIF5–BLCA (DFS)

Open the BLCA breakdown →